Medtronic and Mercy Announce Data Sharing Partnership to Accelerate Medical Device Innovation
October 13 2017 - 10:00AM
YASTEST
Real-World
Clinical Data is Key to Creating More Effective Medical Devices and
Enabling Better Patient Health
DUBLIN and ST. LOUIS - October
13, 2017 - Medtronic plc (NYSE: MDT), the global leader in
medical technology, and Mercy, the fifth largest Catholic health
care system in the U.S., together will establish a new data sharing
and analysis network that helps gather clinical evidence for
medical device innovation and patient access.
Traditional clinical trials can be complex, time
consuming and costly. To address this, Medtronic and Mercy
Technology Services, the IT backbone of Mercy, seek to co-develop a
new way to answer questions about medical device safety and patient
outcomes through access to valuable clinical information captured
during routine patient care. In the initial phase, the new data
network will capture deidentified data from approximately 80,000
patients with heart failure to explore real-world factors that
determine a patient's response to Cardiac Resynchronization Therapy
(CRT) - a clinically proven heart failure treatment option for some
heart failure patients that is designed to help the lower chambers
of the heart beat together in a more synchronized pattern.
This coordinated data network aligns with the Food
and Drug Administration's vision to establish a National Evaluation
System for health Technology (NEST). With a national system, the
FDA aims to quickly generate meaningful insights from routine
clinical care data. The partnership was recently selected by the
Medical Device Innovation Consortium as a Demonstration Project for
its use of scalable methods that generate real-world evidence. This
project will ultimately help shape the model for NEST to provide
faster, more cost-effective regulatory decisions and accelerated
therapy innovation that keeps patients safer and healthier.
"Having the ability to study patient care pathways
and conditions before and after exposure to a medical device is
crucial to understanding how those devices perform outside of the
controlled clinical trial setting," said Dr. Rick Kuntz, SVP of
strategic scientific operations at Medtronic. "By partnering
together, Mercy and Medtronic have set out to create a
comprehensive and economical evidence generation model that
ultimately allows patients to benefit from the latest therapies and
technologies as early as possible."
"This has the potential to improve patient care by
using advanced data analytics," said Dr. Joseph Drozda, Mercy's
director of outcomes research. "Heart failure is a complex,
progressive condition. To more effectively treat patients, we need
a better understanding of how they are responding to treatment and
what leads to better health. This model will lead to evidence-based
insights for our clinical teams, and better health for our
patients."
About Mercy
Mercy, named one of the top five large U.S. health systems in 2017
by Truven, an IBM Watson Health company, serves millions
annually. Mercy includes 44 acute care and specialty (heart,
children's, orthopedic and rehab) hospitals, more than 700
physician practices and outpatient facilities, 40,000 co-workers
and more than 2,000 Mercy Clinic physicians in Arkansas, Kansas,
Missouri and Oklahoma. Mercy also has outreach ministries in
Arkansas, Louisiana, Mississippi and Texas.
About Mercy Technology
Services
Mercy Technology Services provides and manages technology solutions
for Mercy, the nation's first health care provider accredited
by Epic to offer a full suite of EHR solutions to other hospitals,
including Epic in the cloud, implementation and optimization. MTS's
award-winning data analytics integrate care delivery, manage costs
and support a model of care that keeps patients healthier and out
of the hospital.
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin,
Ireland, is among the world's largest medical technology, services
and solutions companies - alleviating pain, restoring health and
extending life for millions of people around the world. Medtronic
employs more than 84,000 people worldwide, serving physicians,
hospitals and patients in approximately 160 countries. The company
is focused on collaborating with stakeholders around the world to
take healthcare Further, Together.
Any forward-looking statements
are subject to risks and uncertainties such as those described in
Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from
anticipated results.
-end-
Contacts:
Jeff Trauring
Public Relations
Medtronic plc
+1-763-505-0159
Ryan Weispfenning
Investor Relations
Medtronic plc
+1-763-505-4626
Nancy Corbett
Mercy Media Relations
+1-405-752-3793
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Medtronic plc via Globenewswire
Medtronic (NYSE:MDT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From Mar 2023 to Mar 2024